Research

Pharmaceutical Sciences

Title :

A clinical drug development programme to evaluate and compare the safety and efficacy of new regimens of Lifecare's Liposomal Amphotericin b (FUNGISOMETM) against currently accepted therapies for the treatment of Kala Azar; A Phase III, Open Label Randomized Trial of Three Single Dose Treatment regimens of FUNGISOMETM ALONE OR IN Combination with Miltefosine compared with single Dose Treatment regimen of AmBisome for visceral Leishmaniasis in India

Area of research :

Pharmaceutical Sciences

Focus area :

Pharmacology and Infectious Diseases

Principal Investigator :

Dr. J N Verma, Lifecare Innovations Private Limited, Gurgaon, Haryana (122018)

Timeline Start Year :

2024

Timeline End Year :

2031

Contact info :

Details

Total Budget (INR):

6,85,59,000

Organizations involved